Considering its drug resistance and that the combination of immunotherapy and chemotherapy is highly effective for SCLC-I9, the combination therapy of RRM1 inhibitor and immunotherapy appears to be the most effective at this stage. This evidence concerns the gene RRM1 and small cell lung carcinoma.